GLPG-1690(ziritaxestat)
GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | GLPG-1690(ziritaxestat) |
|---|---|
| Iupac 化学名称 | 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile |
| 同义词 | GLPG-1690; GLPG 1690; GLPG1690; ziritaxestat. |
| 英文同义词 | GLPG-1690; GLPG 1690; GLPG1690; ziritaxestat. |
| 分子式 | C30H33FN8O2S |
| 分子量 | 588.70 |
| Smile | C(C)C=1N=C2N(C=C(C=C2C)N2CCN(CC2)CC(=O)N2CC(C2)O)C1N(C=1SC(=C(N1)C1=CC=C(C=C1)F)C#N)C |
| InChiKey | REQQVBGILUTQNN-UHFFFAOYSA-N |
| InChi | InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3 |
| Cas号 | 1628260-79-6 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | crystalline solid |
|---|---|
| 纯度 | 98% |
| 存储 | 3 years -20ºCpowder |
| 可溶性 | Soluble in DMSO |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature as non-hazardous chemical. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Desroy N, Housseman C, Bock X, Joncour A, Bienvenu N, Cherel L, Labeguere V, Rondet E, Peixoto C, Grassot JM, Picolet O, Annoot D, Triballeau N, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Blanque R, Cottereaux C, Vandervoort N, Christophe T, Mollat P, Lamers M, Auberval M, Hrvacic B, Ralic J, Oste L, van der Aar E, Brys R, Heckmann B. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methyli midazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2017 May 1. doi: 10.1021/acs.jmedchem.7b00032. [Epub ahead of print] PubMed PMID: 28414242.
